LOC107986385: A Potential Drug Target and Biomarker (G107986385)
LOC107986385: A Potential Drug Target and Biomarker
LOC107986385 is a unique genetic mutation that has been identified in individuals with hereditary transthyretin amyloidosis (HTA), a rare genetic disorder that affects the liver and other organs. This mutation has been found to be associated with an increased risk of developing liver cancer, and researchers are now investigating its potential as a drug target or biomarker.
The LOC107986385 mutation is a single nucleotide polymorphism (SNP) in the coding region of the gene that encodes the protein transmembrane protease serine (TMPRSS1). This gene is part of a family of proteins that are involved in the regulation of cell signaling pathways, and is thought to be involved in the development of various diseases, including HTA.
Research on LOC107986385 has shown that individuals with HTA are at increased risk of developing liver cancer, due to the buildup of abnormal levels of transthyretin amyloid in the liver. This amyloid is thought to disrupt the normal function of the liver cells, leading to the development of cancer.
In addition to its association with HTA, LOC107986385 has also been shown to be associated with other diseases, including cardiovascular disease and neurodegenerative disorders. This suggests that this mutation may have a wide range of potential health impacts, and that it may be a valuable drug target or biomarker for scientists to study.
One potential way to use LOC107986385 as a drug target is by targeting the abnormal levels of transthyretin amyloid that are thought to be caused by this mutation. Researchers have shown that inhibiting the activity of the TMPRSS1 protein, which is encoded by the LOC107986385 mutation, can reduce the amount of transthyretin amyloid that is produced in the liver. This could lead to a reduction in the risk of developing liver cancer and other diseases associated with HTA.
Another potential use of LOC107986385 as a drug target is by targeting the abnormal function of the liver cells that is thought to be caused by this mutation. Researchers have shown that the LOC107986385 mutation disrupts the normal function of the liver cells, leading to the production of harmful levels of certain proteins. Targeting the production of these proteins and restoring the normal function of the liver cells could lead to a reduction in the risk of developing liver cancer and other diseases associated with HTA.
In addition to its potential as a drug target, LOC107986385 has also been shown to be an potential biomarker for the diagnosis and progression of HTA. This is because the abnormal levels of transthyretin amyloid that are thought to be caused by this mutation are also associated with the development of certain symptoms and markers of liver dysfunction. By measuring the levels of transthyretin amyloid and other markers of liver function, researchers may be able to diagnose and monitor the progression of HTA.
Overall, LOC107986385 is an intriguing candidate as a drug target or biomarker for the diagnosis and treatment of HTA. Further research is needed to fully understand its potential health impacts and to develop safe and effective treatments.
Protein Name: Uncharacterized LOC107986385
The "LOC107986385 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC107986385 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC107986400 | LOC107986420 | LOC107986429 | LOC107986440 | LOC107986451 | LOC107986452 | LOC107986453 | LOC107986454 | LOC107986469 | LOC107986517 | LOC107986522 | LOC107986528 | LOC107986537 | LOC107986544 | LOC107986545 | LOC107986561 | LOC107986589 | LOC107986594 | LOC107986595 | LOC107986597 | LOC107986598 | LOC107986606 | LOC107986613 | LOC107986622 | LOC107986623 | LOC107986626 | LOC107986636 | LOC107986649 | LOC107986666 | LOC107986764 | LOC107986766 | LOC107986770 | LOC107986771 | LOC107986772 | LOC107986774 | LOC107986776 | LOC107986777 | LOC107986781 | LOC107986787 | LOC107986800 | LOC107986816 | LOC107986820 | LOC107986836 | LOC107986844 | LOC107986873 | LOC107986892 | LOC107986894 | LOC107986901 | LOC107986903 | LOC107986927 | LOC107986930 | LOC107986952 | LOC107986961 | LOC107986983 | LOC107986996 | LOC107987026 | LOC107987045 | LOC107987049 | LOC107987053 | LOC107987057 | LOC107987064 | LOC107987087 | LOC107987099 | LOC107987121 | LOC107987164 | LOC107987178 | LOC107987211 | LOC107987243 | LOC107987249 | LOC107987251 | LOC107987282 | LOC107987285 | LOC107987299 | LOC107987301 | LOC107987304 | LOC107987407 | LOC107987412 | LOC107987429 | LOC107987435 | LOC107987440 | LOC107987443 | LOC107987449 | LOC107987453 | LOC107987459 | LOC112267867 | LOC112267881 | LOC112267902 | LOC112267956 | LOC112267962 | LOC112267968 | LOC112267978 | LOC112268051 | LOC112268136 | LOC112268248 | LOC112268286 | LOC112268294 | LOC112268416 | LOC114224 | LOC123862 | LOC124901339
